Blueprint Medicines Corp. said on Friday the U.S. drug regulator had put on partial hold an early-stage trial testing its experimental cancer drug due to safety concerns, sending its shares down nearly 6%.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReutersFDAsign.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-10 12:07:432023-02-10 12:07:43U.S. FDA puts partial hold on Blueprint Medicines’ cancer drug trial
